@article{KrebsSolimandoKalogirouetal.2020,
  author    = {Krebs, Markus and Solimando, Antonio Giovanni and Kalogirou, Charis and Marquardt, Andr{\´e} and Frank, Torsten and Sokolakis, Ioannis and Hatzichristodoulou, Georgios and Kneitz, Susanne and Bargou, Ralf and K{\"u}bler, Hubert and Schilling, Bastian and Spahn, Martin and Kneitz, Burkhard},
  title     = {miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro},
  series = {Journal of Clinical Medicine},
  volume    = {9},
  journal   = {Journal of Clinical Medicine},
  number    = {3},
  issn      = {2077-0383},
  doi       = {10.3390/jcm9030670},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-203168},
  year      = {2020},
  abstract  = {Downregulation of miR-221-3p expression in prostate cancer (PCa) predicted overall and cancer-specific survival of high-risk PCa patients. Apart from PCa, miR-221-3p expression levels predicted a response to tyrosine kinase inhibitors (TKI) in clear cell renal cell carcinoma (ccRCC) patients. Since this role of miR-221-3p was explained with a specific targeting of VEGFR2, we examined whether miR-221-3p regulated VEGFR2 in PCa. First, we confirmed VEGFR2/KDR as a target gene of miR-221-3p in PCa cells by applying Luciferase reporter assays and Western blotting experiments. Although VEGFR2 was mainly downregulated in the PCa cohort of the TCGA (The Cancer Genome Atlas) database, VEGFR2 was upregulated in our high-risk PCa cohort (n = 142) and predicted clinical progression. In vitro miR-221-3p acted as an escape mechanism from TKI in PC3 cells, as displayed by proliferation and apoptosis assays. Moreover, we confirmed that Sunitinib induced an interferon-related gene signature in PC3 cells by analyzing external microarray data and by demonstrating a significant upregulation of miR-221-3p/miR-222-3p after Sunitinib exposure. Our findings bear a clinical perspective for high-risk PCa patients with low miR-221-3p levels since this could predict a favorable TKI response. Apart from this therapeutic niche, we identified a partially oncogenic function of miR-221-3p as an escape mechanism from VEGFR2 inhibition.},
  language  = {en}
}
@article{VerghoKneitzKalogirouetal.2014,
  author    = {Vergho, Daniel Claudius and Kneitz, Susanne and Kalogirou, Charis and Burger, Maximilian and Krebs, Markus and Rosenwald, Andreas and Spahn, Martin and L{\"o}ser, Andreas and Kocot, Arkadius and Riedmiller, Hubertus and Kneitz, Burkhard},
  title     = {Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava},
  doi       = {10.1371/journal.pone.0109877},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-113633},
  year      = {2014},
  abstract  = {Clear cell renal cell carcinoma (ccRCC) characterized by a tumor thrombus (TT) extending into the inferior vena cava (IVC) generally indicates poor prognosis. Nevertheless, the risk for tumor recurrence after nephrectomy and thrombectomy varies. An applicable and accurate prediction system to select ccRCC patients with TT of the IVC (ccRCC/TT) at high risk after nephrectomy is urgently needed, but has not been established up to now. To our knowledge, a possible role of microRNAs (miRs) for the development of ccRCC/TT or their impact as prognostic markers in ccRCC/TT has not been explored yet. Therefore, we analyzed the expression of the previously described onco-miRs miR-200c, miR-210, miR-126, miR-221, let-7b, miR-21, miR-143 and miR-141 in a study collective of 74 ccRCC patients. Using the expression profiles of these eight miRs we developed classification systems that accurately differentiate ccRCC from non-cancerous renal tissue and ccRCC/TT from tumors without TT. In the subgroup of 37 ccRCC/TT cases we found that miR-21, miR-126, and miR-221 predicted cancer related death (CRD) accurately and independently from other clinico-pathological features. Furthermore, a combined risk score based on the expression of miR-21, miR-126 and miR-221 was developed and showed high sensitivity and specificity to predict cancer specific survival (CSS) in ccRCC/TT. Using the combined risk score we were able to classify ccRCC/TT patients correctly into high and low risk cases. The risk stratification by the combined risk score (CRS) will benefit from further cohort validation and might have potential for clinical application as a molecular prediction system to identify high- risk ccRCC/TT patients.},
  language  = {en}
}
@article{KneitzKalogirouSpahnetal.2013,
  author    = {Kneitz, Burkhard and Kalogirou, Charis and Spahn, Martin and Krebs, Markus and Joniau, Steven and Lerut, Evelyne and Burger, Maximilian and Scholz, Claus-J{\"u}rgen and Kneitz, Susanne and Riedmiller, Hubertus},
  title     = {MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer},
  series = {International Journal of Molecular Sciences},
  journal   = {International Journal of Molecular Sciences},
  doi       = {10.3390/ijms141121414},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-97321},
  year      = {2013},
  abstract  = {The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70\% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa.},
  language  = {en}
}
@article{FussOtherHeinzeetal.2021,
  author    = {Fuss, Carmina Teresa and Other, Katharina and Heinze, Britta and Landwehr, Laura-Sophie and Wiegering, Armin and Kalogirou, Charis and Hahner, Stefanie and Fassnacht, Martin},
  title     = {Expression of the chemokine receptor CCR7 in the normal adrenal gland and adrenal tumors and its correlation with clinical outcome in adrenocortical carcinoma},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {22},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13225693},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-250112},
  year      = {2021},
  abstract  = {Background: The chemokine receptor CCR7 is crucial for an intact immune function, but its expression is also associated with clinical outcome in several malignancies. No data exist on the expression of CCR7 in adrenocortical tumors. Methods: CCR7 expression was investigated by qRT-PCR and immunohistochemistry in 4 normal adrenal glands, 59 adrenocortical adenomas, and 181 adrenocortical carcinoma (ACC) samples. Results: CCR7 is highly expressed in the outer adrenocortical zones and medulla. Aldosterone-producing adenomas showed lower CCR7 protein levels (H-score 1.3 ± 1.0) compared to non-functioning (2.4 ± 0.5) and cortisol-producing adenomas (2.3 ± 0.6), whereas protein expression was variable in ACC (1.8 ± 0.8). In ACC, CCR7 protein expression was significantly higher in lymph node metastases (2.5 ± 0.5) compared to primary tumors (1.8±0.8) or distant metastases (2.0 ± 0.4; p < 0.01). mRNA levels of CCR7 were not significantly different between ACCs, normal adrenals, and adrenocortical adenomas. In contrast to other tumor entities, neither CCR7 protein nor mRNA expression significantly impacted patients' survival. Conclusion: We show that CCR7 is expressed on mRNA and protein level across normal adrenals, benign adrenocortical tumors, as well as ACCs. Given that CCR7 did not influence survival in ACC, it is probably not involved in tumor progression, but it could play a role in adrenocortical homeostasis.},
  language  = {en}
}
@phdthesis{Kalogirou2012,
  author    = {Kalogirou, Charis Alexis Thomas},
  title     = {Untersuchungen zur Funktion und Expression von miR-205 und miR-221 im Prostatakarzinom unter besonderer Beachtung von miR-205 als Prognosemarker beim Hochrisiko-Patienten},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-85549},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Das Prostatakarzinom (PCa) ist weltweit das h{\"a}ufigste Malignom des Mannes mit weiter steigenden Inzidenz. Leider ist es bisher mit den gebr{\"a}uchlichen Prognosefaktoren nicht m{\"o}glich, diesen klinisch sehr heterogenen Tumor vor einer chirurgischen Therapie hinsichtlich des postoperativen Rezidivrisikos zu charakterisieren. Die Einf{\"u}hrung neuer, hochsensitiver Biomarker, die diese Aufgabe zuverl{\"a}ssig erf{\"u}llen k{\"o}nnen, stellt vor allem f{\"u}r die Entwicklung individualisierter Therapieregimes von Patienten mit einem high-risk-PCa eine aktuelle Herausforderung dar. MicroRNAs r{\"u}ckten in den letzten Jahren als potentielle Biomarker zunehmend in den wissenschaftlichen Fokus. Sie stellen kleine RNA-Molek{\"u}le dar, welche posttranskriptionell die Genexpression in Organismen steuern und auch in der Regulation von Tumorsuppressoren und Onkogenen eine Rolle spielen. Differentielle Expressionslevels verschiedener RNAs wurden in sehr vielen Tumorentit{\"a}ten, wie auch dem PCa beobachtet. Vorarbeiten aus unserem Labor zeigten, dass zwei microRNAs, miR-205 und miR-221, im PCa sehr stark unterexprimiert werden. Im Falle von mir-221 konnte zudem bereits eine Korrelation mit dem klinischen Verlauf und der Prognose des high-risk-PCa dargestellt werden. Aufbauend auf diesen Vorarbeiten sollte in einem Teilprojekt der vorliegenden Arbeit die tumorsuppressive Funktion von miR-221 im PCa untersucht werden. Mittels transienter {\"U}berexpression von miR-221 in PCa-Zelllinien konnte die Bedeutung von miR-221 als Regulator der Proliferation in PCa-Zellen beschrieben werden. Um die molekulare Wirkweise von miR-221 weiter darzustellen, wurde die posttranskriptionelle Inhibierung von p27kip1 und c-kit, zwei bekannten miR-221-Zielgenen, untersucht. In sogenannten Luciferase-Assays konnte eine direkte Interaktion von miR-221 mit definierten Sequenzen im 3'-untranslatierten Bereich (=3'UTR) beider Gene nachgewiesen werden. Erwartungsgem{\"a}ß wurde aber in prim{\"a}ren PCa-Tumoren, die anders wie viele andere Tumorentit{\"a}ten eine reduzierte miR-221-Expression aufwiesen, keine {\"U}berexpression des potentiellen Tumorsuppressors p27kip1 beobachtet. Somit ist nachgewiesen, dass miR-221 zwar prinzipiell den Tumorsuppressor p27kip1 regulieren kann, dass allerdings dieser Mechanismus in prim{\"a}ren PCa f{\"u}r die Regulation des Tumorsuppressors p27kip1 keine {\"u}bergeordnete Rolle spielt. Anders verh{\"a}lt es sich bei dem potentiellen Onkogen c-kit. Die von mir druchgef{\"u}hrten Untersuchungen k{\"o}nnen erstmals eine direkte Interaktion von c-kit und miR-221 in PCa-Zellen nachweisen. Somit kann die beschriebene Proliferations-inhibierung und Apoptoseinduktion nach ektopischer miR-221-{\"U}berexpression im Zellmodell mit einer miR-221-vermittelten c-kit-Inhibierung in Zusammenhang gebracht werden. Dieses Ergebnis wird durch den Nachweise einer inversen Assoziation der mir-221- und ckit-Expression in prim{\"a}ren PCa-F{\"a}llen untermauert (nicht gezeigte Ergebnisse). Betrachtet man diese Ergebnisse in Zusammenhang mit der bekannten tumor-progressiven Funktionen von c-kit, k{\"o}nnte durch die fehlende/reduzierte miR-221-Inhibierung der c-kit-Translation die Entstehung und Progression vieler PCas erkl{\"a}rt werden. In einem zweiten Projektansatz wurde die Bedeutung und Funktion von miR-205 als m{\"o}glicher Tumorsuppressor im PCa untersucht. Dabei kann gezeigt werden, dass mir-205 ebenfalls in der Lage ist, nach transienter {\"U}berexpression die Proliferation von PCa-Zellen zu inhibieren. Um molekulare Mechanismen und Wirkweisen von mir-205 zu untersuchen, wurden im Zellmodell die Expression der Onkogene HER2/neu und HER3, beides vorausgesagte miR-205-Zielgene, analysiert. Es konnte gezeigt werden, dass in PCa-Zellen die Unterexpression von HER3 und HER/neu mit der ektopischen {\"U}berexpression von miR-205 assoziiert ist. Die HER2/neu-Expression konnte zus{\"a}tzlich auch im prim{\"a}ren Tumor mit der miR-205-Expression invers assoziiert werden, wodurch die Regulation dieses Zielgens auf nativer Ebene verifiziert wurde. Ein weiterer Fokus dieser Arbeit konzentrierte sich auf die Fragestellung, ob sich miR-205 als Prognosemarker im high-risk-PCa eignen k{\"o}nnte. Hierzu wurden in einem etablierten high-risk-PCa-Studienkollektiv die Expression von mir-205 analysiert und anschließend Korrelations- und {\"U}berlebensanalysen durchgef{\"u}hrt. Es konnte statistisch keine Assoziation zwischen der miR-205-Expression und verschiedenen Prognoseparametern, die in der Klinik pr{\"a}operativ prognostische Vorraussagekraft besitzen, hergestellt werden. Allerdings fiel auf, dass Karzinome, die miR-205 relativ schwach herabregulierten, ein signifikant schlechteres prognostisches Outcome und {\"U}berlebensnachteile zeigten, im Vergleich zu Tumoren, die eine starke miR-205-Regulation aufweisen. Somit konnten im Hochrisikokollektiv mit Hilfe der miR-205-Expressionsanalyse Karzinome identifiziert werden, die ein erh{\"o}htes Rezidivrisiko aufweisen. Die hier vorgelegten Untersuchungen stellen also erste Hinweise dar, dass miR-205 als unabh{\"a}ngiger prognostischer Marker im PCa Verwendung finden k{\"o}nnte. Zusammenfassend kann in der vorgelegten Arbeit gezeigt werden, dass die microRNAs miR-205 und miR-221 zwei tumorsuppressive RNAs im PCa darstellen. Eine m{\"o}gliche zuk{\"u}nftige Implementation der Expressionsanalysen von miR-221 und/oder miR-205 als Progressionsmarker stellt eine vielversprechende M{\"o}glichkeit dar, in Zukunft die Prognose und vielleicht auch die Therapie des PCa zu verbessern.},
  subject      = {Prostatakrebs},
  language  = {de}
}
@article{KienerChenKrebsetal.2019,
  author    = {Kiener, Mirjam and Chen, Lanpeng and Krebs, Markus and Grosjean, Joȅl and Klima, Irena and Kalogirou, Charis and Riedmiller, Hubertus and Kneitz, Burkhard and Thalmann, George N. and Snaar-Jagalska, Ewa and Spahn, Martin and Kruithof-de Julio, Marianna and Zoni, Eugenio},
  title     = {miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo},
  series = {BMC Cancer},
  volume    = {19},
  journal   = {BMC Cancer},
  doi       = {10.1186/s12885-019-5819-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325762},
  year      = {2019},
  abstract  = {Background Despite latest advances in prostate cancer (PCa) therapy, PCa remains the third-leading cause of cancer-related death in European men. Dysregulation of microRNAs (miRNAs), small non-coding RNA molecules with gene expression regulatory function, has been reported in all types of epithelial and haematological cancers. In particular, miR-221-5p alterations have been reported in PCa. Methods miRNA expression data was retrieved from a comprehensive publicly available dataset of 218 PCa patients (GSE21036) and miR-221-5p expression levels were analysed. The functional role of miR-221-5p was characterised in androgen- dependent and androgen- independent PCa cell line models (C4-2 and PC-3M-Pro4 cells) by miR-221-5p overexpression and knock-down experiments. The metastatic potential of highly aggressive PC-3M-Pro4 cells overexpressing miR-221-5p was determined by studying extravasation in a zebrafish model. Finally, the effect of miR-221-5p overexpression on the growth of PC-3M-Pro4luc2 cells in vivo was studied by orthotopic implantation in male Balb/cByJ nude mice and assessment of tumor growth. Results Analysis of microRNA expression dataset for human primary and metastatic PCa samples and control normal adjacent benign prostate revealed miR-221-5p to be significantly downregulated in PCa compared to normal prostate tissue and in metastasis compared to primary PCa. Our in vitro data suggest that miR-221-5p overexpression reduced PCa cell proliferation and colony formation. Furthermore, miR-221-5p overexpression dramatically reduced migration of PCa cells, which was associated with differential expression of selected EMT markers. The functional changes of miR-221-5p overexpression were reversible by the loss of miR-221-5p levels, indicating that the tumor suppressive effects were specific to miR-221-5p. Additionally, miR-221-5p overexpression significantly reduced PC-3M-Pro4 cell extravasation and metastasis formation in a zebrafish model and decreased tumor burden in an orthotopic mouse model of PCa. Conclusions Together these data strongly support a tumor suppressive role of miR-221-5p in the context of PCa and its potential as therapeutic target.},
  language  = {en}
}
@article{KotlyarKrebsSolimandoetal.2023,
  author    = {Kotlyar, Mischa J. and Krebs, Markus and Solimando, Antonio Giovanni and Marquardt, Andr{\´e} and Burger, Maximilian and K{\"u}bler, Hubert and Bargou, Ralf and Kneitz, Susanne and Otto, Wolfgang and Breyer, Johannes and Vergho, Daniel C. and Kneitz, Burkhard and Kalogirou, Charis},
  title     = {Critical evaluation of a microRNA-based risk classifier predicting cancer-specific survival in renal cell carcinoma with tumor thrombus of the inferior vena cava},
  series = {Cancers},
  volume    = {15},
  journal   = {Cancers},
  number    = {7},
  issn      = {2072-6694},
  doi       = {10.3390/cancers15071981},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-311040},
  year      = {2023},
  abstract  = {(1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC\(^{IVC}\)) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier — containing miR-21-5p, miR-126-3p and miR-221-3p expression — which significantly predicted the cancer-specific survival (CSS) of ccRCC\(^{IVC}\) patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC\(^{IVC}\), we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan-Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan-Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC\(^{IVC}\) according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC\(^{IVC}\) cohort.},
  language  = {en}
}
@article{KalogirouSchwingerKocotetal.2021,
  author    = {Kalogirou, Charis and Schwinger, Marcel and Kocot, Arkadius and Riedmiller, Hubertus},
  title     = {Troubleshooting of failed continence mechanisms in the ileocecal pouch: Operative technique and long-term results of the intussuscepted ileal nipple valve},
  series = {International Journal of Urology},
  volume    = {28},
  journal   = {International Journal of Urology},
  number    = {11},
  doi       = {10.1111/iju.14654},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259431},
  pages     = {1105-1111},
  year      = {2021},
  abstract  = {Objectives To provide a detailed step-by-step operative technique, and to report on long-term functional and metabolic outcomes in secondary continence mechanisms in the form of secondary intussuscepted ileal nipple valves in revisional surgery of ileocecal pouches. Methods From May 1997 to May 2015, 18 female and 10 male patients suffering from dysfunctional primary continence mechanisms of their ileocecal pouch underwent revisonal surgery to create a secondary ileal nipple valve at our tertiary referral center. The average follow-up period was 65.4 months. Results After surgery, 24 patients were continent by day and night, and four patients showed minor incontinence with the use of a safety pad. The average frequency of clean intermittent catheterization decreased both during the day and at night. The diameter of the catheters used for clean intermittent catheterization increased significantly. No patient showed stomal stenosis, change of stool habits or metabolic situation in the follow-up period. Furthermore, the creation of the secondary ileal nipple valves did not affect the capacity of the reservoir. In the long-term follow up, two patients required the construction of a third continence mechanism, making for an overall success rate of 92\% in the study group. Conclusion To our knowledge, this is the first study of long-term results after the creation of secondary ileal nipple valves. We provide evidence that the creation of a secondary ileal nipple valve is a safe and reliable procedure for continence restoration in ileocecal pouches with excellent functional and metabolic long-term outcomes.},
  language  = {en}
}
@article{JordanBroeerFischeretal.2022,
  author    = {Jordan, Martin C. and Br{\"o}er, David and Fischer, Christian and Heilig, Philipp and Gilbert, Fabian and H{\"o}lscher-Doht, Stefanie and Kalogirou, Charis and Popp, Kevin and Grunz, Jan-Peter and Huflage, Henner and Jakubietz, Rafael G. and Erg{\"u}n, S{\"u}leyman and Meffert, Rainer H.},
  title     = {Development and preclinical evaluation of a cable-clamp fixation device for a disrupted pubic symphysis},
  series = {Communications Medicine},
  volume    = {2},
  journal   = {Communications Medicine},
  number    = {1},
  doi       = {10.1038/s43856-022-00227-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-299800},
  year      = {2022},
  abstract  = {Background Traumatic separation of the pubic symphysis can destabilize the pelvis and require surgical fixation to reduce symphyseal gapping. The traditional approach involves open reduction and the implantation of a steel symphyseal plate (SP) on the pubic bone to hold the reposition. Despite its widespread use, SP-fixation is often associated with implant failure caused by screw loosening or breakage. Methods To address the need for a more reliable surgical intervention, we developed and tested two titanium cable-clamp implants. The cable served as tensioning device while the clamp secured the cable to the bone. The first implant design included a steel cable anterior to the pubic symphysis to simplify its placement outside the pelvis, and the second design included a cable encircling the pubic symphysis to stabilize the anterior pelvic ring. Using highly reproducible synthetic bone models and a limited number of cadaver specimens, we performed a comprehensive biomechanical study of implant stability and evaluated surgical feasibility. Results We were able to demonstrate that the cable-clamp implants provide stability equivalent to that of a traditional SP-fixation but without the same risks of implant failure. We also provide detailed ex vivo evaluations of the safety and feasibility of a trans-obturator surgical approach required for those kind of fixation. Conclusion We propose that the developed cable-clamp fixation devices may be of clinical value in treating pubic symphysis separation.},
  language  = {en}
}
@article{HartrampfHeinrichSeitzetal.2020,
  author    = {Hartrampf, Philipp E. and Heinrich, Marieke and Seitz, Anna Katharina and Brumberg, Joachim and Sokolakis, Ioannis and Kalogirou, Charis and Schirbel, Andreas and K{\"u}bler, Hubert and Buck, Andreas K. and Lapa, Constantin and Krebs, Markus},
  title     = {Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy — Do Different Software Solutions Deliver Comparable Results?},
  series = {Journal of Clinical Medicine},
  volume    = {9},
  journal   = {Journal of Clinical Medicine},
  number    = {5},
  issn      = {2077-0383},
  doi       = {10.3390/jcm9051390},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-205893},
  year      = {2020},
  abstract  = {(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: \(^{68}\)Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland-Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.},
  language  = {en}
}